Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)

NCT00116831 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00116831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
August 31, 2008
Enrollment
672 (actual)
Sites
156

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis